20 completed, 15 recruiting, 9 unknown, 5 not yet recruiting. 18 Phase 2, 13 Phase 3, 8 Phase 4, 6 Not applicable, 5 Phase 1.
Follow letermovir: new trials by email Literature Review of letermovir trials Research Report on letermovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Letermovir for R+ Study Letermovir - Kidney Transplant, Liver Transplant | Phase 4 | Not yet recruiting | University of Wisconsin, Madison | 146 | 2026-10-01 | 2026-09-29 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Letermovir vs Valganciclovir in CMV R+ Kidney Transplant Letermovir, Valganciclovir CMV Prophylaxis - CMV Infection, CMV | Phase 4 | Not yet recruiting | Elisabeth Kincaide | 300 | 2026-05-01 | 2026-05-08 |
| A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077) Letermovir - Cytomegalovirus Prophylaxis | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 40 | 2026-03-30 | 2026-10-30 |
| Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients Letermovir, Placebo, Valganciclovir/Ganciclovir - CMV, Lung Transplant Recipient | Phase 4 | Recruiting | University Health Network, Toronto | 40 | 2025-12-24 | 2026-02-17 |
| Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis Letermovir - EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis | Not applicable | Recruiting | Beijing Children's Hospital | 80 | 2025-10-01 | 2026-03-23 |
| Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant Letermovir, Valganciclovir - CMV Viremia, Heart Transplant Infection | Phase 2 / Phase 3 | Recruiting | Columbia University | 150 | 2025-09-12 | 2026-10-02 |
| Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy Letermovir - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 2 | Recruiting | Seoul National University Hospital | 40 | 2025-09-11 | 2025-12-03 |
| Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis Letermovir 480 mg [PREVYMIS] - End-Stage Kidney Disease (ESKD) | Phase 1 | Not yet recruiting | Jason A Roberts | 20 | 2025-09-01 | 2025-08-03 |
| Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients Letermovir, Valganciclovir - Kidney Transplant | Phase 4 | Recruiting | First Affiliated Hospital Xi'an Jiaotong University | 290 | 2025-05-13 | 2025-12-05 |
| A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Letermovir - Congenital Cytomegalovirus Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 3 | 2025-02-19 | 2026-08-03 |
| Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT Letermovir (0-24w）, Letermovir (0-14w） - Cytomegalovirus Infections, CMV | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 330 | 2024-12-16 | 2026-01-21 |
| Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell Letermovir - Cell Therapy | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2024-12-12 | 2026-08-07 |
| The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients Hematopoietic Cell Transplant, Letermovir - Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant | Not applicable | Recruiting | M.D. Anderson Cancer Center | 105 | 2024-11-20 | 2026-06-15 |
| Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection Letermovir - HIV | Phase 2 | Not yet recruiting | University College, London | 36 | 2024-10-01 | 2024-10-04 |
| Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections Letermovir, Valganciclovir, Letermovir placebo - Cytomegalovirus Infection | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2024-08-14 | 2026-01-02 |
| Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients Letermovir - Cytomegalovirus Infections, Kidney Transplant Infection | Phase 3 | Recruiting | University of Wisconsin, Madison | 90 | 2024-08-08 | 2026-06-11 |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients Biospecimen Collection, Letermovir - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 3 | Recruiting | Children's Oncology Group | 105 | 2024-07-11 | 2026-10-06 |
| CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT Letermovir - Hematologic Malignancy | Phase 3 | Active not recruiting | Ruijin Hospital | 250 | 2024-07-01 | 2025-12-15 |
| CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT Letermovir, CMV T Cell Immunity Panel (CMV-TCIP), CMV DNA PCR - CMV, Allogeneic Stem Cell Transplantation | Phase 2 | Recruiting | University of California, Irvine | 50 | 2024-06-27 | 2026-07-21 |
Showing 20 of 53. Sign in to see all of them.
Cytomegalovirus Infections (22) · Hematologic Neoplasms (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Neutropenia (3) · Hodgkin Disease (2) · Leukemia, Myeloid, Accelerated Phase (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myeloid, Chronic-Phase (2) · Lymphoma, Non-Hodgkin (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Primary Myelofibrosis (2) · Disease (1) · Graft vs Host Disease (1)
Merck Sharp & Dohme LLC (7) · Assistance Publique - Hôpitaux de Paris (3) · The First Affiliated Hospital of Soochow University (3) · City of Hope Medical Center (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · M.D. Anderson Cancer Center (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Tufts Medical Center (2) · University of Wisconsin, Madison (2) · AiCuris Anti-infective Cures AG (1) · Amy C. Sherman, MD (1) · Anhui Provincial Hospital (1) · Beijing Children's Hospital (1) · Cao Weijie (1) · Children's Oncology Group (1)
United States (25) · China (11) · France (7) · Germany (4) · Canada (3) · Japan (3) · Spain (3) · Australia (2) · Colombia (2) · Italy (2) · Mexico (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Austria (1)
Ryotaro Nakamura (2) · Xiaojin Wu, Prof. (2) · Amy C Sherman, MD (1) · Bojan Vrtovec, MD, PhD (1) · Caitlin W Elgarten (1) · Carolina A Berini, BSc, PhD (1) · David Al-Adra, MD (1) · Fareed Khawaja, MBBS (1) · Fernanda Silveira (1) · Gaurav Gupta, MD (1) · Genovefa Papanicolaou (1) · George Chen, MD (1)
PMID 24806159, PMID 27682069, PMID 29211658, PMID 29319768, PMID 30137245, PMID 31081566, PMID 31179485, PMID 31978003, PMID 32134486, PMID 33197929, PMID 33440077, PMID 34674258, PMID 36464218, PMID 36690406, PMID 37279999, PMID 38142695, PMID 38241643, PMID 38615067, PMID 38700045, PMID 38853607, PMID 40824644, PMID 41321121, PMID 41403238, PMID 41895456, PMID 42639594
2018 (2), 2023 (2), 2017 (1), P30CA033572 (1), U24CA196173 (1), U54AI150225 (1), UG1CA189955 (1)